TPE and RAC Audit Support for DMEPOS Supplier: Diabetic Supplies and CGM Documentation Compliance

Continuous glucose monitors and diabetic testing supplies represent an extremely high-volume DMEPOS category, and CMS’s own reporting has identified this category as one of the leading sources of improper Medicare payment, with insufficient or missing documentation accounting for the substantial majority of identified errors. Because CGM and diabetic supply coverage depends on a recurring cycle of initial qualifying visits and ongoing six-month adherence documentation, rather than a one-time qualifying determination, suppliers must maintain a systematic, continuously operating documentation process capable of tracking these recurring requirements accurately across their entire diabetic supply beneficiary population.

This article explains the LCD-based coverage framework governing continuous glucose monitors and diabetic testing supplies, the recurring documentation cycle suppliers must manage, why this category draws such frequent TPE and RAC attention, and how suppliers should structure a compliance program addressing both effectively. It closes with how HealthBridge US supports DMEPOS Suppliers strengthening diabetic supplies and CGM documentation.

The CGM Coverage Framework

Continuous glucose monitor coverage requires that the beneficiary be insulin-treated or have a documented history of problematic hypoglycemia satisfying specific criteria outlined in the applicable LCD, and coverage depends on an in-person or Medicare-approved telehealth visit with the treating practitioner within six months before the CGM is initially ordered, during which the practitioner evaluates the beneficiary’s diabetes control and confirms the applicable coverage criteria are met. Following this initial qualifying visit, coverage continuation depends on a recurring requirement for an in-person or Medicare-approved telehealth visit at least every six months, specifically documenting the beneficiary’s adherence to the CGM regimen and ongoing diabetes treatment plan and supporting that continued CGM supply use remains medically necessary.

Because a pharmacist is not considered a statutorily recognized treating practitioner for Medicare purposes, documentation from a pharmacist alone does not satisfy the continued coverage visit requirement, and suppliers should ensure the six-month visit documentation they rely upon specifically reflects an encounter with a qualifying treating practitioner rather than another member of the beneficiary’s broader care team.

Diabetic Testing Supply Documentation Requirements

Diabetic testing supplies, including blood glucose test strips and lancets, similarly require ongoing documentation supporting medical necessity, and where a beneficiary’s prescribed testing frequency exceeds the usual utilization amounts CMS’s coverage policy generally anticipates, continued dispensing of quantities exceeding these usual amounts requires the treating practitioner to specifically verify, at least every six months, the beneficiary’s adherence to the high utilization testing regimen actually prescribed. Suppliers dispensing testing supplies at a frequency above the standard utilization threshold should ensure this heightened documentation requirement is tracked and satisfied specifically, rather than assuming general diabetes management documentation automatically extends to support an above-standard testing frequency.

Why This Category Generates Frequent Improper Payment Findings

CMS’s own compliance reporting has specifically identified that no documentation accounted for a substantial majority of improper payments for glucose monitors during recent reporting periods, with insufficient documentation and other errors accounting for most of the remainder, reflecting a persistent, well-documented pattern of documentation gaps specific to this equipment and supply category. Because CGM and diabetic supply coverage depends on a recurring, ongoing documentation cycle rather than a single initial qualifying determination, suppliers face a distinctive compliance challenge: even a supplier with excellent initial qualifying documentation practices can accumulate significant improper payment exposure over time if its recurring six-month adherence documentation tracking is not equally rigorous and systematically maintained.

TPE and RAC reviewers specifically examine whether the initial qualifying visit documentation satisfies the applicable LCD’s specific coverage criteria, whether recurring six-month adherence visits are documented by a qualifying treating practitioner rather than a non-qualifying provider, and whether high-utilization testing supply quantities are supported by the required heightened documentation.

Building a Comprehensive Documentation Tracking Process

Given the recurring, cyclical nature of CGM and diabetic supply documentation requirements, suppliers should implement systematic tracking tools specifically flagging each beneficiary’s upcoming six-month documentation checkpoint well in advance of the deadline, proactively reaching out to treating practitioners to schedule and obtain the required visit documentation rather than discovering after the fact that a checkpoint was missed. This tracking should specifically confirm that six-month visit documentation reflects an encounter with a qualifying treating practitioner, and should separately flag beneficiaries receiving above-standard testing supply quantities for the corresponding heightened documentation requirement.

Building an Effective TPE or RAC Response

When a TPE review or RAC audit challenges CGM or diabetic supply billing, the response should include the complete initial qualifying visit documentation establishing that applicable coverage criteria were satisfied, along with documentation of every required six-month adherence visit occurring since initiation, clearly identifying the qualifying treating practitioner for each visit. Where high-utilization testing supplies are at issue, the response should include the specific six-month verification documentation supporting the elevated testing frequency actually prescribed and dispensed.

Common CGM and Diabetic Supply Documentation Gaps

Several recurring gaps appear in CGM and diabetic supply reviews, consistent with CMS’s own reported improper payment findings. Missing documentation entirely, whether for the initial qualifying visit or a required six-month adherence visit, represents by far the most frequently cited and most consequential issue in this category. Six-month adherence documentation attributed to a pharmacist or other non-qualifying provider rather than a statutorily recognized treating practitioner is another specific and recurring gap. Missing heightened verification documentation supporting above-standard testing supply utilization quantities rounds out a frequent finding specific to diabetic testing supplies.

Preparing for Post-Payment Review Across a Growing Beneficiary Population

As a supplier’s diabetic supply and CGM beneficiary population grows, the operational burden of tracking every beneficiary’s individual six-month checkpoint calendar grows correspondingly, and suppliers that do not scale their tracking infrastructure alongside this growth face increasing risk that individual checkpoints will be missed simply due to volume rather than any deliberate process failure. Suppliers should periodically reassess whether their current tracking systems and staffing remain adequate to the size of their actual current beneficiary population, treating this reassessment as a standing operational discipline rather than a one-time setup decision made when the supplier’s diabetic supply business was considerably smaller than its current scale, since a tracking process that worked well at a modest beneficiary volume can quietly begin to fail as that volume grows substantially larger over time.

Coordinating Supplier Tracking Systems and Treating Practitioner Relationships

Because CGM and diabetic supply documentation compliance depends on a recurring cycle of treating practitioner visits occurring on a schedule the supplier itself must actively monitor, sustained compliance requires proactive supplier engagement with treating practitioners well beyond the initial qualifying order. Suppliers should build automated or systematically managed tracking specifically calibrated to each beneficiary’s six-month checkpoint calendar, and should establish clear, standing communication channels with high-volume referring practices to streamline the process of obtaining timely six-month adherence documentation across a supplier’s full diabetic beneficiary population.

Addressing the Transition From Testing Supplies to CGM Coverage

Many beneficiaries transition from traditional blood glucose testing supplies to continuous glucose monitoring over the course of their diabetes management, and suppliers should treat this transition as its own distinct documentation event requiring a fresh initial qualifying visit specifically addressing the CGM-specific coverage criteria, rather than assuming a beneficiary’s prior testing supply documentation automatically extends to support the different coverage requirements applicable to CGM technology. Suppliers managing beneficiaries through this kind of equipment transition should build a clear internal process flagging the transition point and triggering the appropriate CGM-specific qualifying documentation collection, ensuring the switch itself does not inadvertently create a documentation gap during the handoff between the two supply categories.

Building Beneficiary and Caregiver Education Into the Compliance Process

Because CGM and diabetic supply coverage continuation depends on the beneficiary actually attending recurring six-month treating practitioner visits, suppliers benefit from proactively educating beneficiaries and, where applicable, caregivers on the importance of these recurring visits not just for clinical diabetes management but for maintaining uninterrupted equipment and supply coverage. Beneficiaries who understand that missing a six-month visit can jeopardize continued coverage are often more motivated to keep these appointments consistently, and suppliers that build this educational messaging into their standard beneficiary communication practices, through appointment reminders or other outreach, tend to experience fewer coverage gaps driven by beneficiaries simply missing or postponing a required checkpoint visit.

Reviewing Denial Patterns to Target Process Improvement

Suppliers should track their own CGM and diabetic supply denial history specifically, distinguishing between denials tied to missing initial qualifying documentation, missing or non-qualifying six-month adherence documentation, and inadequate high-utilization verification, since each of these distinct denial categories points to a different underlying process gap requiring a different corrective focus. A supplier whose denials consistently trace to six-month adherence documentation gaps, for example, should prioritize strengthening its recurring checkpoint tracking system specifically, rather than applying a generic, undifferentiated process improvement effort across all three distinct documentation categories without regard to where the supplier’s own actual denial pattern is concentrated.

Auditing Refill Documentation Alongside Recurring Visit Checkpoints

Beyond the recurring six-month treating practitioner visit requirement, diabetic supply refills carry their own documentation expectations, including evidence that the beneficiary has actually been using previously dispensed supplies at a rate consistent with the quantities being newly refilled, and suppliers should build refill request verification directly into their broader compliance process rather than treating refill dispensing as a purely administrative, non-clinical function disconnected from the underlying medical necessity documentation framework. A refill request pattern suggesting supplies are being dispensed faster than a beneficiary’s documented usage would reasonably support can itself become a red flag during a TPE or RAC review, and suppliers that proactively monitor refill timing against expected utilization patterns are better positioned to catch and address this kind of discrepancy before it becomes the subject of an external audit finding.

How HealthBridge US Supports Your DMEPOS Supplier Business

Continuous glucose monitors and diabetic testing supplies generate a documented majority of improper payments tied specifically to missing or insufficient recurring documentation, making systematic, ongoing documentation tracking essential rather than optional for this high-volume category. HealthBridge US supports DMEPOS Suppliers with CGM and diabetic supply documentation audits, six-month checkpoint tracking system design, treating practitioner coordination, and TPE and RAC audit response support. If your DMEPOS business wants to strengthen diabetic supply and CGM documentation, build recurring checkpoint tracking, or needs support responding to an active TPE or RAC review, HealthBridge US is here to help — contact our team to discuss your DMEPOS supplier compliance needs, and let our team help you build a durable process that keeps pace with your growing diabetic supply beneficiary population.

References

• Centers for Medicare & Medicaid Services. LCD - Glucose Monitors (L33822). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822

• Centers for Medicare & Medicaid Services. “Billing and Coding: Glucose Monitor” (Article A52464). https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464

• Centers for Medicare & Medicaid Services. “Glucose Monitoring Supplies” (Medicare Provider Compliance Tips). https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies

• Centers for Medicare & Medicaid Services. LCD - Implantable Continuous Glucose Monitors (I-CGM) (L38743). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38743

• Centers for Medicare & Medicaid Services. “Targeted Probe and Educate (TPE).” https://www.cms.gov/medicare/review/targeted-probe-educate

• Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Chapter 29 (Appeals). https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c29.pdf

HealthBridge US is here to help. Our compliance specialists support DMEPOS Suppliers with diabetic supply and CGM documentation review and TPE and RAC response — contact us to protect your business’s reimbursement.